First Patient Treated With Titan Pharmaceuticals' Subdermal Implant For Parkinson's Disease
Titan Pharmaceuticals, Inc. | October 11, 2017
Titan Pharmaceuticals, Inc, a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura long-term, continuous drug delivery technology, announced today that the first patient has been treated in a Phase 1/2 trial of the company's ropinirole implant intended for the treatment of the signs and symptoms of idiopathic Parkinson's disease.